Medical researchers have demonstrated that lutetium-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer.
New therapeutic agent proves more effective treatment for advanced prostate cancer
Science Daily - 5 Jan 2017 19:32
Medical researchers have demonstrated that lutetium-177-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer.
Share this Article
Recommended